Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigating combination benefit of PD1 and LAG3 co-blockade using an engineered cellular bioassay.

International immunopharmacology - 1 Jun 2023

Bhagwat Bhagyashree, de Waal Malefyt Rene, Willingham Aarron

Abstract excerpt

LAG3 and PD1 are both immunomodulatory receptor that act by inhibiting activation of T cells, producing a more immunosuppressive environment. Even with the recent clinical success of PD1 and LAG3 co-blockade, signal transduction downstream of LAG3 remains largely unknown. We have leveraged an engineered Jurkat (T cell) and Raji (APC) co-culture system to assess simultaneous blockade of PD1 and LAG3 pathways using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Antibodies, Blocking
Share to CD28 Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Jurkat Cells

Share to Phenotype

Source

Identifiers

PMID: 37044037
DOI: 10.1016/j.intimp.2022.109566

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigating combination benefit of PD1 and LAG3 co-blockade using an engineered cellular bioassay.PMID 37044037Read ↗

PD-1/LAG-3 Dysfunctionality Signatures in Human CancersSemantic proximity Read ↗

LAG Time in the Era of Immunotherapy—New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene‐3Semantic proximity Read ↗

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.Semantic proximity Read ↗

Defining mechanisms of co-inhibitory receptor Lymphocyte Activation Gene-3 (LAG-3) in T cellsSemantic proximity Read ↗

Understanding LAG-3 SignalingSemantic proximity Read ↗

Anti-Correlation of KLRG1 and PD-1 Expression in Human Tumor CD8 T CellsSemantic proximity Read ↗

LAG-3: from molecular functions to clinical applicationsSemantic proximity Read ↗

Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexitySemantic proximity Read ↗

Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor ModelsSemantic proximity Read ↗

Development and characterization of Novel Small Molecule Inhibitors Targeting LAG-3 ProteinSemantic proximity Read ↗

Control of T lymphocyte fate decisions by PI3K signalingSemantic proximity Read ↗

Cbl-b inhibition promotes less differentiated phenotypes of T cells with enhanced cytokine production.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.